Gemcitabine Pancreatic Cancer
Links shared publicly online about this topic
ASCO: Radioimmunotherapy + gemcitabine shows promise for pancreatic cancer
healthimaging.com — “The results of an ongoing phase I/II study for treating advanced pancreatic cancer with a combination therapy of Immunomedics' antibody, clivatuzumab tetraxetan, (90Y-hPAM4) and anticancer drug gemcitabine, which demonstrated therapeutic activity at two 90Y dose levels with minimal hematologic toxicity, was presented with positive findings at the seventh annual Gastrointestinal Cancers Symposium in Orlando, Fla. this week.” View full resource at healthimaging.com
Most Recently Shared on January 28, 2010 at 2:22 pm By:
Health Imaging & IT Health Magazine
ASCO: Radioimmunotherapy + gemcitabine shows promise for pancreatic cancer http://ow.ly/16rvem
Nab-Paclitaxel Plus Gemcitabine Shows Promise In Advanced Pancreatic Cancer
medicalnewstoday.com — “Washington - A combination of nab-paclitaxel (AbraxaneR for Injectable Suspension) and gemcitabine improves survival when used as first-line treatment in patients with advanced pancrea” View full resource at medicalnewstoday.com
Most Recently Shared on April 23, 2010 at 2:28 pm By:
Nab-Paclitaxel Plus Gemcitabine Shows Promise In Advanced Pancreatic Cancer http://mnt.to/3BFg #cancer
Oncology Article | Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells
mdlinx.com — “Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells” View full resource at mdlinx.com
Most Recently Shared on October 31, 2011 at 9:43 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells: Cancer Letters http://t.co/f7H7Q2EY #oncology
Researchers identify critical marker of response to gemcitabine in pancreatic cancer
physorg.com — “A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University.” View full resource at physorg.com
Most Recently Shared on June 4, 2009 at 3:22 pm By:
Researchers identify critical marker of response to gemcitabine in pancreatic cancer http://tinyurl.com/o2bgnw
Researchers Identify Critical Marker of Response to Gemcitabine in Pancreatic Cancer
newswise.com — “A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University.” View full resource at newswise.com
Most Recently Shared on June 4, 2009 at 4:25 pm By:
Researchers Identify Critical Marker of Response to Gemcitabine in Pancreatic Cancer http://bit.ly/4Em0Bq
Low-Dose Radiation Boosts Effect of Gemcitabine in Pancreatic Cancer | Radiology
medicexchange.com — “Combining low-dose fractionated radiation therapy with gemcitabine (Gemzar) might potentiate the effect of gemcitabine, but with lower toxicity, in patients with advanced pancreatic cancer.” View full resource at medicexchange.com
Most Recently Shared on November 12, 2010 at 9:55 am By:
Alex van Klaveren Health Social Media
Low-Dose Radiation Boosts Effect of Gemcitabine in Pancreatic Cancer: Combining low-dose fractionated radiation ... http://bit.ly/cXNDNA
Low-Dose Radiation Boosts Effect of Gemcitabine in Pancreatic Cancer | Radiology
medicexchange.com — “Combining low-dose fractionated radiation therapy with gemcitabine (Gemzar) might potentiate the effect of gemcitabine, but with lower toxicity, in patients with advanced pancreatic cancer.” View full resource at medicexchange.com
Most Recently Shared on November 12, 2010 at 9:55 am By:
Alex van Klaveren Health Social Media
Latest News- Low-Dose Radiation Boosts Effect of Gemcitabine in Pancreatic Cancer http://bit.ly/b6CY7B #radiology #healthit
Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced Pancreatic Cancer - MPR
empr.com — “Data from the BAYPAN study presented at the American College of Clinical Oncology’s 2011 Annual Meeting did not support the addition of sorafenib to gemcitabine therapy in the treatment of advanced pancreatic cancer (APC), in contrast to an earlier Phase I study that demonstrated that this combination was well tolerated and had activity in APC patients.” View full resource at empr.com
Most Recently Shared on June 6, 2011 at 9:01 pm By:
#asco2011 Addition of Sorafenib to Gemcitabine Does Not Improve Survival in Advanced… http://goo.gl/fb/XYOKi
FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer - OncologySTAT
oncologystat.com — “N Engl J Med. 2011 May 12;364(19):1817-1825 - T Conroy, F Desseigne, M Ychou, O Bouché, R Guimbaud, Y Bécouarn, A Adenis, JL Raoul, S Gourgou-Bourgade, C de la Fouchardière, J Bennouna, JB Bachet” View full resource at oncologystat.com
Most Recently Shared on May 19, 2011 at 4:02 pm By:
OncologySTAT Health Site and Oncology
Story of the Week With Expert Commentary: FOLFIRINOX: New Standard Treatment for Metastatic Pancreatic Cancer http://tinyurl.com/3ulhsob
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study : The Lancet Oncology
thelancet.com — “Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. By - Dr Hedy L Kindler MD, Tatsuya Ioka MD, D...” View full resource at thelancet.com
Most Recently Shared on February 8, 2011 at 3:48 pm By:
Reporting a phase 3 trial of gemcitabine plus axitinib in patients with advanced pancreatic cancer. http://fb.thelancet.com/JLh
Oncology Medical News about Gemcitabine
mdlinx.com — “Gemcitabine Sensitivity Can Be Induced in Pancreatic Cancer Cells through Modulation of miR-200 and miR-21 Expression by Curcumin or Its Analogue CDF” View full resource at mdlinx.com
Most Recently Shared on May 20, 2010 at 8:12 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Gemcitabine Sensitivity Can Be Induced in Pancreatic Cancer Cells through Modulation of miR-200 and miR-2... http://bit.ly/bqc2Gx #oncology
AmpliMed Reports Results From AMP-019; A Randomized Double Blind Trial Of Gemcitabine/Placebo Vs. Gemcitabine/Amplimexon In Advanced Pancreatic Cancer
medicalnewstoday.com — “AmpliMed Corporation, a cancer therapeutics company, announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III tri” View full resource at medicalnewstoday.com
Most Recently Shared on July 12, 2010 at 5:06 pm By:
MNT Clinical Trials Health News
AmpliMed Reports Results From AMP-019; A Randomized Double Blind Trial Of Gemcitabine/Placebo Vs. Gemcitabine/Amplimex... http://mnt.to/3FYV
No Superior Survival With Gemcitabine in Pancreatic Cancer, Says ESPAC-3 - QualityPoint Technologies
qualitypointtech.net — “Compared with the combination of fluorouracil plus folinic acid, gemcitabine did not result in improved survival among patients with completely resected pancreatic cancer. Medscape Medical News” View full resource at qualitypointtech.net
Most Recently Shared on September 8, 2010 at 6:15 pm By:
No Superior Survival With Gemcitabine in Pancreatic Cancer, Says ESPAC-3: Compared with the combination of fluorou... http://bit.ly/dbOCYs
CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer
news-medical.net — “Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC.” View full resource at news-medical.net
Most Recently Shared on May 26, 2010 at 3:16 pm By:
News-Medical.Net Health News and Oncology
Oncology News: CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancrea... http://bit.ly/b4osYo
Gastroenterology News - Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer |3992011
mdlinx.com — “Gastroenterology Medical Article: Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer” View full resource at mdlinx.com
Most Recently Shared on March 23, 2012 at 6:44 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathwa... http://t.co/bScXqpjW #GI
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Health Imaging & IT
Health Imaging & IT | Images, Information & Knowledge Across the Enterprise
-
MNT Cancer News
The latest cancer news published daily. Articles from research centers, universities and prestigious journals.
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
Advertisement
